EVANSTON, Ill.--(BUSINESS WIRE)--March 22, 2006--Northfield Laboratories Inc. (NASDAQ: NFLD) announced today that Steven A. Gould, M.D., Chairman and Chief Executive Officer, briefed Senate Finance Committee staff members this afternoon about the Company's clinical experience with its human hemoglobin-based oxygen carrying red cell substitute, PolyHeme. In particular, Dr. Gould reviewed the current Pivotal Phase III trial, which is being conducted at Level I trauma centers across the United States. He was accompanied by Ernest E. "Gene" Moore, M.D., Chief of Surgery and Trauma Services, Denver Health Medical Center, lead investigator for the study. Dr. Moore discussed the need for a red cell substitute, his extensive clinical experience with PolyHeme, and his research into the immunomodulatory effects of blood in the early care of the trauma patient.
